Colgate-Palmolive (CL) Getting Somewhat Favorable Press Coverage, Analysis Finds

Share on StockTwits

News stories about Colgate-Palmolive (NYSE:CL) have trended somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Colgate-Palmolive earned a daily sentiment score of 0.57 on their scale. InfoTrie also assigned media coverage about the company an news buzz score of 5 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock’s share price in the immediate future.

These are some of the news stories that may have impacted Colgate-Palmolive’s ranking:

CL traded up $2.90 during trading on Friday, hitting $63.80. 9,735,092 shares of the stock traded hands, compared to its average volume of 5,944,362. The stock has a market capitalization of $53.19 billion, a P/E ratio of 22.23, a PEG ratio of 3.01 and a beta of 0.75. The company has a quick ratio of 0.77, a current ratio of 1.11 and a debt-to-equity ratio of 64.85. Colgate-Palmolive has a 12-month low of $57.41 and a 12-month high of $77.91.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings results on Friday, October 26th. The company reported $0.72 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.72. The business had revenue of $3.85 billion during the quarter, compared to analysts’ expectations of $3.89 billion. Colgate-Palmolive had a net margin of 13.55% and a return on equity of 12,004.60%. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.73 EPS. Sell-side analysts expect that Colgate-Palmolive will post 2.96 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, November 15th. Shareholders of record on Friday, October 19th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, October 18th. This represents a $1.68 annualized dividend and a yield of 2.63%. Colgate-Palmolive’s payout ratio is currently 58.54%.

A number of equities research analysts have recently issued reports on CL shares. Argus reaffirmed a “buy” rating and issued a $75.00 price objective (up previously from $72.00) on shares of Colgate-Palmolive in a research note on Tuesday, September 18th. UBS Group raised shares of Colgate-Palmolive from a “neutral” rating to a “buy” rating and upped their price objective for the company from $70.00 to $75.00 in a research note on Wednesday, July 18th. Zacks Investment Research raised shares of Colgate-Palmolive from a “sell” rating to a “hold” rating in a research note on Tuesday, September 18th. Barclays set a $64.00 price objective on shares of Colgate-Palmolive and gave the company a “hold” rating in a research note on Monday, July 30th. Finally, Wells Fargo & Co reaffirmed a “hold” rating and issued a $64.00 price objective on shares of Colgate-Palmolive in a research note on Friday, July 27th. Four investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and two have assigned a buy rating to the stock. Colgate-Palmolive has an average rating of “Hold” and an average price target of $68.06.

In other news, CFO Henning I. Jakobsen sold 1,015 shares of the firm’s stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $67.05, for a total value of $68,055.75. Following the completion of the sale, the chief financial officer now directly owns 36,193 shares of the company’s stock, valued at approximately $2,426,740.65. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Vice Chairman Dennis J. Hickey sold 120,000 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $65.72, for a total transaction of $7,886,400.00. Following the completion of the sale, the insider now directly owns 202,414 shares of the company’s stock, valued at $13,302,648.08. The disclosure for this sale can be found here. Insiders have sold a total of 149,811 shares of company stock valued at $9,835,756 in the last three months. 1.02% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This report was first reported by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://baseballnewssource.com/2018/11/10/colgate-palmolive-cl-getting-somewhat-favorable-press-coverage-analysis-finds/2973671.html.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, and other related products.

Further Reading: How to Profit and Limit Losses With Stop Orders

Insider Buying and Selling by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.